Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aimmune Therapeutics, Inc.

https://www.aimmune.com/

Latest From Aimmune Therapeutics, Inc.

Novartis’s Peanut Allergy Setback Perks Up Rivals

Opportunity could knock for the smaller but more specialized players in the peanut allergy space now that Novartis has halted trials of its investigational IgE inhibitor ligelizumab.

Clinical Trials Immune Disorders

Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts

Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.

Deals Strategy

Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire

Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.

Business Strategies Launches

2021: A Record-Breaking Year For ‘Smart’ Pricing And Access Deals In England

NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.

United Kingdom Market Access
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Allergen Research Corporation (ARC)
UsernamePublicRestriction

Register